Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Reference: USP

Nilotinib (trade name Tasigna) is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML).
Reference: In-house and USP

Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumours. FDA approved on September 27, 2012.
Reference: In-house and USP

Sorafenib interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases.Sorafenib inhibits multiple tyrosine kinases and the growth of cancer cells.
Reference: In-house and USP

Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.
Reference: In-house and USP

Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006.
Reference: In-house and USP